The rationale for the study stemmed from the need to improve treatment options for patients with metastatic breast cancer. Existing treatments often failed to provide long-term benefits, and researchers aimed to explore whether adding bevacizumab to paclitaxel could extend progression-free survival (PFS), overall survival (OS), and improve overall response rates.
